Verónica Pulido Sanz

Mrs. Verónica Pulido Sanz

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2011 in Human Mutation
Verified
Journal Article
Closed access
PDF file
Victor Martinez-GlezVictor Martinez-Glez
Victor Martinez-Glez
MVMaria Valencia
Maria Valencia
José Caparros-MartinJosé Caparros-Martin
José Caparros-Martin
MAMona Aglan
Mona Aglan
STSamia Temtamy
Samia Temtamy
VRVictor L. Ruiz-Perez
Victor L. Ruiz-Perez
Herein, we have studied a consanguineous Egyptian family with two children diagnosed with severe autosomal recessive osteogenesis imperfecta (AR‐OI) and a large umbilical hernia. Homozygosity mapping in this family showed lack of linkage to any of the previously known AR‐OI genes, but revealed a 10.27 MB homozygous region on chromosome 8p in the two affected sibs, which comprised the procollagen I C‐terminal propeptide (PICP) endopeptidase gene BMP1. Mutation analysis identified both patients with a Phe249Leu homozygous missense change within the BMP1 protease domain involving a residue, which is conserved in all members of the astacin group of metalloproteases. Type I procollagen analysis in supernatants from cultured fibroblasts demonstrated abnormal PICP processing in patient‐derived cells consistent with the mutation causing decreased BMP1 function. This was further confirmed by overexpressing wild type and mutant BMP1 longer isoform (mammalian Tolloid protein [mTLD]) in NIH3T3 fibroblasts and human primary fibroblasts. While overproduction of normal mTLD resulted in a large proportion of proα1(I) in the culture media being C‐terminally processed, proα1(I) cleavage was not enhanced by an excess of the mutant protein, proving that the Phe249Leu mutation leads to a BMP1/mTLD protein with deficient PICP proteolytic activity. We conclude that BMP1 is an additional gene mutated in AR‐OI. Hum Mutat 33:343–350, 2012.

11 June 2012 in Human Mutation
Verified
Journal Article
Closed access
PDF file
MPMaria Trinidad Puig-Hervás
Maria Trinidad Puig-Hervás
STSamia Temtamy
Samia Temtamy
MAMona Aglan
Mona Aglan
MVMaria Valencia
Maria Valencia
Victor Martinez-GlezVictor Martinez-Glez
Victor Martinez-Glez
VRVictor L. Ruiz-Perez
Victor L. Ruiz-Perez
PLOD2 and FKBP10 are genes mutated in Bruck syndrome (BS), a condition resembling osteogenesis imperfecta (OI), but that is also typically associated with congenital joint contractures. Herein, we sought mutations in six consanguineous BS families and detected changes in either PLOD2 or FKBP10 in all cases. Two probands were found with a homozygous frameshift mutation in the alternative exon 13a of PLOD2, indicating that specific inactivation of the longer protein isoform encoded by this gene is sufficient to cause BS. In addition, by homozygosity mapping, followed by a candidate gene approach, we identified a homozygous donor splice site mutation in PLOD2 in a patient with autosomal‐recessive OI (AR‐OI). Screening of additional samples also revealed compound heterozygous mutations in PLOD2 in two brothers, one affected with mild AR‐OI and the other with mild BS. Thus, PLOD2 in addition to causing BS is also associated with AR‐OI phenotypes of variable severity. Hum Mutat 33:1444–1449, 2012.

23 April 2013 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
José Caparros-MartinJosé Caparros-Martin
José Caparros-Martin
MVMaría Valencia
María Valencia
VSVerónica Pulido Sanz
Verónica Pulido Sanz
Victor Martinez-GlezVictor Martinez-Glez
Victor Martinez-Glez
IRInmaculada Rueda‐Arenas
Inmaculada Rueda‐Arenas
MAMona Aglan
Mona Aglan

28 February 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
RGRaúl García
Raúl García
VSVerónica Pulido Sanz
Verónica Pulido Sanz
SOSara Orellana-Muñoz
Sara Orellana-Muñoz
CNCésar Nombela
César Nombela
CACarlos R. Vázquez de Aldana
Carlos R. Vázquez de Aldana
Javier ArroyoJavier Arroyo
Javier Arroyo
Post-transcriptional control of mRNA is a key event in the regulation of gene expression. From yeast to human cells, P-bodies are cytoplasmic RNA-protein aggregates that play an essential role in this process, particularly under stress conditions. In this work, we show that in the model yeast Saccharomyces cerevisiae cell wall stress induces the formation of these structures. This effect is dependent on multiple elements in the Cell Wall Integrity (CWI) MAPK signalling pathway, a signal transduction cascade responsible for the maintenance of cell integrity under adverse environmental conditions. Remarkably, P-body assembly requires the catalytic activity of the MAPK of the pathway, Slt2/Mpk1. In accordance with the control exerted by this signalling pathway, the timing of P-body formation is similar to that of the activation of the CWI pathway. Noticeably, mRNAs whose expression is regulated by this pathway localize in P-bodies after the cell is exposed to stress following a temporal pattern coincident with CWI pathway activation. Moreover, when these mRNAs are overexpressed in a mutant background unable to form visible P-bodies, the cells show hypersensitivity to agents that interfere with cell wall integrity, supporting that they play a role in the mRNA lifecycle under stress conditions.

2 November 2014 in Epigenetics
Verified
Journal Article
Open access
OPOlga Pernía
Olga Pernía
CBCristobal Belda-Iniesta
Cristobal Belda-Iniesta
VSVerónica Pulido Sanz
Verónica Pulido Sanz
MCMaría Cortes-Sempere
María Cortes-Sempere
CRCarlos Rodríguez-Antolín
Carlos Rodríguez-Antolín
ICInmaculada Ibanez de Caceres
Inmaculada Ibanez de Caceres
The methylation status of the IGFBP-3 gene is strongly associated with cisplatin sensitivity in patients with non-small cell lung cancer (NSCLC). In this study, we found in vitro evidence that linked the presence of an unmethylated promoter with poor response to radiation. Our data also indicate that radiation might sensitize chemotherapy-resistant cells by reactivating IGFBP-3-expression through promoter demethylation, inactivating the PI3K/AKT pathway. We also explored the IGFBP-3 methylation effect on overall survival (OS) in a population of 40 NSCLC patients who received adjuvant therapy after R0 surgery. Our results indicate that patients harboring an unmethylated promoter could benefit more from a chemotherapy schedule alone than from a multimodality therapy involving radiotherapy and platinum-based treatments, increasing their OS by 2.5 y (p = .03). Our findings discard this epi-marker as a prognostic factor in a patient population without adjuvant therapy, indicating that radiotherapy does not improve survival for patients harboring an unmethylated IGFBP-3 promoter.

26 March 2020 in Cancers
Verified
Journal Article
Open access
PDF file
OPOlga Pernia
Olga Pernia
ASAna Sastre-Perona
Ana Sastre-Perona
CRCarlos Rodríguez-Antolín
Carlos Rodríguez-Antolín
ÁGÁlvaro García
Álvaro García
MBMaria Palomares Bralo
Maria Palomares Bralo
ICInmaculada Ibanez de Caceres
Inmaculada Ibanez de Caceres
Despite often leading to platinum resistance, platinum-based chemotherapy continues to be the standard treatment for many epithelial tumors. In this study we analyzed and validated the cytogenetic alterations that arise after treatment in four lung and ovarian paired cisplatin-sensitive/resistant cell lines by 1-million microarray-based comparative genomic hybridization (array-CGH) and qRT-PCR methodologies. RNA-sequencing, functional transfection assays, and gene-pathway activity analysis were used to identify genes with a potential role in the development of this malignancy. The results were further explored in 55 lung and ovarian primary tumors and control samples, and in two extensive in silico databases. Long-term cell exposure to platinum induces the frequent deletion of ITF2 gene. Its expression re-sensitized tumor cells to platinum and recovered the levels of Wnt/β-catenin transcriptional activity. ITF2 expression was also frequently downregulated in epithelial tumors, predicting a worse overall survival. We also identified an inverse correlation between ITF2 and HOXD9 expression, revealing that Non-small cell lung cancer (NSCLC) patients with lower expression of HOXD9 had a better overall survival rate. We defined the implication of ITF2 as a molecular mechanism behind the development of cisplatin resistance probably through the activation of the Wnt-signaling pathway. This data highlights the possible role of ITF2 and HOXD9 as novel therapeutic targets for platinum resistant tumors.